Autologous CD19/BCMA dual-target CAR-T

CD19/BCMA dual-target chimeric antigen receptor T-cell · Beijing Boren Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Autologous CD19/BCMA dual-target CAR-T, covering 2026-01-22 to 2026-01-22. Get the full timeline:

Most recent: Clinical Trial Update: Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases [Phase 1]